Nanobiotix S.A. (0QAV.L)

EUR 3.04

(3.06%)

Total Liabilities Summary of Nanobiotix S.A.

Nanobiotix S.A.'s latest annual total liabilities in 2023 was 95.74 Million EUR , up 10.28% from previous year.
Nanobiotix S.A.'s latest quarterly total liabilities in 2024 Q2 was 108.45 Million EUR , down 0.0% from previous quarter.
Nanobiotix S.A. reported annual total liabilities of 86.81 Million EUR in 2022, up 15.78% from previous year.
Nanobiotix S.A. reported annual total liabilities of 74.97 Million EUR in 2021, up 17.96% from previous year.
Nanobiotix S.A. reported quarterly total liabilities of 95.74 Million EUR for 2023 FY, up 10.28% from previous quarter.
Nanobiotix S.A. reported quarterly total liabilities of 95.74 Million EUR for 2023 Q4, down 0.0% from previous quarter.

Annual Total Liabilities Chart of Nanobiotix S.A. (2023 - 2012)

Historical Annual Total Liabilities of Nanobiotix S.A. (2023 - 2012)

Year	Total Liabilities	Total Liabilities Growth
2023	95.74 Million EUR	10.28%
2022	86.81 Million EUR	15.78%
2021	74.97 Million EUR	17.96%
2020	63.56 Million EUR	9.38%
2019	58.11 Million EUR	81.88%
2018	31.95 Million EUR	135.9%
2017	13.54 Million EUR	4.15%
2016	13 Million EUR	20.33%
2015	10.8 Million EUR	60.38%
2014	6.73 Million EUR	58.29%
2013	4.25 Million EUR	27.93%
2012	3.32 Million EUR	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q2	108.45 Million EUR	0.0%
2023 FY	95.74 Million EUR	10.28%
2023 Q4	95.74 Million EUR	0.0%
2023 Q2	94.19 Million EUR	0.0%
2022 Q4	86.81 Million EUR	0.0%
2022 Q2	78.83 Million EUR	0.0%
2022 FY	86.81 Million EUR	15.78%
2021 FY	74.97 Million EUR	17.96%
2021 Q4	74.97 Million EUR	0.0%
2021 Q2	82.48 Million EUR	0.0%
2020 Q2	66.95 Million EUR	0.0%
2020 FY	63.56 Million EUR	9.38%
2020 Q4	63.56 Million EUR	0.0%
2019 Q4	58.11 Million EUR	0.0%
2019 FY	58.11 Million EUR	81.88%
2019 Q2	54.57 Million EUR	0.0%
2018 FY	31.95 Million EUR	135.9%
2018 Q4	31.95 Million EUR	0.0%
2018 Q2	11.57 Million EUR	0.0%
2017 FY	13.54 Million EUR	4.15%
2017 Q4	13.54 Million EUR	0.0%
2017 Q2	11.44 Million EUR	0.0%
2016 Q2	9.62 Million EUR	0.0%
2016 FY	13 Million EUR	20.33%
2016 Q4	13 Million EUR	0.0%
2015 Q4	10.8 Million EUR	0.0%
2015 Q2	8.89 Million EUR	0.0%
2015 FY	10.8 Million EUR	60.38%
2014 FY	6.73 Million EUR	58.29%
2014 Q4	6.73 Million EUR	0.0%
2014 Q2	4.43 Million EUR	0.0%
2013 FY	4.25 Million EUR	27.93%
2013 Q4	4.25 Million EUR	0.0%
2013 Q2	3.41 Million EUR	0.0%
2012 Q4	3.32 Million EUR	0.0%
2012 Q3	3.32 Million EUR	0.0%
2012 FY	3.32 Million EUR	0.0%

Peer Total Liabilities Comparison of Nanobiotix S.A.

Name	Total Liabilities	Total Liabilities Difference
Boiron SA	198.7 Million EUR	51.817%
Laboratorios Farmaceuticos Rovi, S.A.	256.39 Million EUR	62.658%
Vetoquinol SA	165.12 Million EUR	42.019%
Valneva SE	341.14 Million EUR	71.936%
AB Science S.A.	46.5 Million EUR	-105.857%
PHAXIAM Therapeutics S.A.	25.69 Million EUR	-272.602%
Vivoryon Therapeutics N.V.	4.54 Million EUR	-2005.564%
BioSenic S.A.	32.26 Million EUR	-196.739%
ABIVAX Société Anonyme	131.05 Million EUR	26.945%
Formycon AG	387.61 Million EUR	75.3%